Literature DB >> 25947224

[New aspects of tumor pathology of the pituitary].

W Saeger1.   

Abstract

Pituitary adenomas have to be studied in detail for structural characteristics, especially regarding the degree of granulation and immunohistochemical hormone expression, such as growth hormone (GH), prolactin, adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH), follicle stimulating hormone (FSH), luteinizing hormone (LH) and proliferation markers (e.g. Ki-67 and p53) for correlation to clinical data and assessment of the prognosis. If histological and immunostaining data do not correlate to the patient data, explanations for the discrepancies must be found. All active adenoma types can also be present as inactive, so-called silent adenomas showing the same features. An increased Ki-67 index (> 3%), significant nuclear expression of protein p53 and mitoses are characteristic of atypical adenomas. Up to now the biological relevance of these atypical adenomas, especially their role as preneoplasms for pituitary carcinomas has not been fully elucidated. The only proof of a pituitary carcinoma is the existence of metastases. Extensive local invasion and a greatly increased Ki-67 index are not sufficient for this diagnosis. Craniopharyngiomas have to be classified into adamantinomatous types (intrasellar and suprasellar) and papillary types (only suprasellar). Regressive changes are found in adamantinomatous types only. Strong regression may lead to difficulties in the differential diagnosis of Rathke's cleft cysts with squamous metaplasia. Demonstration of nuclear expression of beta-catenin in these cases enables the diagnosis of craniopharyngioma. Papillary craniopharyngiomas are characterized by BRAF mutations that may be helpful in the differential diagnosis. All pituicytomas of the neurohypophysis, all spindle cell oncocytomas of the anterior pituitary and all granular cell tumors of the posterior pituitary express thyroid transcription factor 1 (TTF-1) and are thought to be variants of a common uniform spindle cell tumor of the pituitary.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25947224     DOI: 10.1007/s00292-015-0025-z

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  32 in total

1.  Comments on the WHO 2004 classification of pituitary tumors.

Authors:  Stefan Wolfsberger; Engelbert Knosp
Journal:  Acta Neuropathol       Date:  2005-11-23       Impact factor: 17.088

Review 2.  Pathology of excessive production of growth hormone.

Authors:  B W Scheithauer; K Kovacs; R V Randall; E Horvath; E R Laws
Journal:  Clin Endocrinol Metab       Date:  1986-08

Review 3.  Predictive markers of pituitary adenoma behavior.

Authors:  George Kontogeorgos
Journal:  Neuroendocrinology       Date:  2006-10-13       Impact factor: 4.914

4.  [Combined neuronal and endocrine tumors of the sellar region].

Authors:  W Saeger; D K Lüdecke; M Losa
Journal:  Pathologe       Date:  1997-11       Impact factor: 1.011

Review 5.  Xanthomatous pituitary lesions: a report of two cases and review of the literature.

Authors:  Morton G Burt; Adrienne L Morey; Jenny J Turner; Malcolm Pell; John P Sheehy; Ken K Y Ho
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

6.  Invasiveness of pituitary adenomas.

Authors:  D Sautner; W Saeger
Journal:  Pathol Res Pract       Date:  1991-06       Impact factor: 3.250

Review 7.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Authors:  Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2007-02       Impact factor: 6.664

8.  Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.

Authors:  W Saeger; B Lüdecke; D K Lüdecke
Journal:  Exp Clin Endocrinol Diabetes       Date:  2007-12-10       Impact factor: 2.949

9.  The spectrum of malignancy in craniopharyngioma.

Authors:  Fausto J Rodriguez; Bernd W Scheithauer; Shigeru Tsunoda; Kalman Kovacs; Sergio Vidal; David G Piepgras
Journal:  Am J Surg Pathol       Date:  2007-07       Impact factor: 6.394

Review 10.  Aggressive pituitary adenomas--diagnosis and emerging treatments.

Authors:  Antonio Di Ieva; Fabio Rotondo; Luis V Syro; Michael D Cusimano; Kalman Kovacs
Journal:  Nat Rev Endocrinol       Date:  2014-05-13       Impact factor: 43.330

View more
  2 in total

1.  Remitting long-standing major depression in a multiple sclerosis patient with several concurrent conditions.

Authors:  Navzer D Sachinvala; Angeline Stergiou; Duane E Haines
Journal:  Neuropsychiatr Dis Treat       Date:  2018-10-04       Impact factor: 2.570

2.  Post-Craniopharyngioma and Cranial Nerve-VI Palsy Update on a MS Patient with Major Depression and Concurrent Neuroimmune Conditions.

Authors:  Navzer D Sachinvala; Angeline Stergiou; Duane E Haines; Armen Kocharian; Andrew Lawton
Journal:  Brain Sci       Date:  2019-10-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.